Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Fenretinide and Lonafarnib in Treating Patients With Advanced or Recurrent Head and Neck Cancer

This study has been terminated.
(Slow Accrual.)
Sponsor:
Collaborator:
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00103090
First received: February 7, 2005
Last updated: November 12, 2012
Last verified: November 2012

February 7, 2005
November 12, 2012
January 2005
January 2006   (final data collection date for primary outcome measure)
  • Modulation of intermediated biological endpoints at 6 weeks after treatment [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
  • Maximum tolerated dose (MTD) [ Time Frame: 21 day course ] [ Designated as safety issue: Yes ]
    MTD derived from lack of dose limiting toxicities (DLT) in 4 differing dose levels.
Not Provided
Complete list of historical versions of study NCT00103090 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Fenretinide and Lonafarnib in Treating Patients With Advanced or Recurrent Head and Neck Cancer
A Phase IB Randomized Translational Study of Fenretinide (4-HPR) in Combination With SCH66336, a Farnesyl Transferase Inhibitor, in Patients With Advanced or Recurrent Head and Neck Cancer

RATIONALE: Drugs, such as fenretinide and lonafarnib, may stop the growth of head and neck cancer by blocking blood flow to the tumor. Fenretinide may also help tumor cells become normal cells. Lonafarnib may also stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving fenretinide together with lonafarnib may kill more tumor cells.

PURPOSE: This randomized phase I trial is studying the side effects and best dose of fenretinide and lonafarnib in treating patients with advanced or recurrent head and neck cancer.

OBJECTIVES:

Primary

  • Determine the biological activity and tolerability of fenretinide and lonafarnib in patients with advanced or recurrent squamous cell carcinoma of the head and neck.
  • Determine the toxicity profile of this regimen in these patients.
  • Determine the maximum tolerated dose of this regimen in these patients.

Secondary

  • Determine the dose-limiting toxicity of this regimen in these patients.
  • Determine a recommended phase II dose of this regimen in these patients.

OUTLINE: This is a dose-escalation study followed by a randomized study.

  • Dose-escalation portion: Patients receive oral fenretinide twice daily on days 1-7 and oral lonafarnib twice daily on days 1*-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of fenretinide and lonafarnib until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity.

  • Randomized portion: After the dose-escalation portion of this study is completed, additional patients (including patients who participate in the dose-escalation portion of this study) are accrued and randomized to 1 of 4 dose levels. All patients receive fenretinide and lonafarnib as in the dose-escalation portion of this study.

NOTE: *Lonafarnib is not administered on day 1 of course 1.

After completion of study treatment, patients are followed every 3 months for 2 years.

PROJECTED ACCRUAL: A total of 40 patients will be accrued for this study.

Interventional
Phase 1
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Head and Neck Cancer
  • Drug: Fenretinide
    Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
    Other Name: 4-HPR
  • Drug: Lonafarnib
    Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
    Other Names:
    • SCH66336
    • SCH 66336
    • Sarasar
Experimental: Fenretinide + Lonafarnib
Lonafarnib daily for 21 days each cycle and with Fenretinide daily on days 1-7 only. On day 1 of cycle 1, Fenretinide only then beginning Lonafarnib on day 2 of cycle 1.
Interventions:
  • Drug: Fenretinide
  • Drug: Lonafarnib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Terminated
1
November 2006
January 2006   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Histologically confirmed squamous cell carcinoma of the head and neck

    • Advanced or recurrent disease
  • Considered incurable by standard measures
  • Tumor tissue accessible for biopsy

PATIENT CHARACTERISTICS:

Age

  • Any age

Performance status

  • stern Cooperative Oncology Group (ECOG) 0-1

Life expectancy

  • Not specified

Hematopoietic

  • White Blood Count (WBC) ≥ 3,000/mm^3
  • Absolute neutrophil count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3
  • Hemoglobin ≥ 9.0 g/dL

Hepatic

  • Bilirubin ≤ 2.0 mg/dL
  • Albumin ≥ 2.5 g/dL
  • Aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) ≤ 2.5 times upper limit of normal (ULN) AND alkaline phosphatase normal OR
  • Alkaline phosphatase ≤ 4 times Upper Limit of Normal (ULN) AND Aspartate aminotransferase (AST or SGOT) and/or alanine aminotransferase (ALT or SGPT) normal

Renal

  • Creatinine < 2 mg/dL

Cardiovascular

  • No history of uncontrolled heart disease
  • No arrhythmia
  • No angina
  • No congestive heart failure
  • No other heart condition that cannot be controlled with regular ongoing medication

Gastrointestinal

  • Able to swallow oral medication
  • No requirement for total parenteral nutrition with lipids

Neurological

  • No significant neuropathy
  • No neurotoxicity ≥ grade 3 from prior anticancer treatment

Other

  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective double-method contraception during and for at least 1 month after study participation
  • No signs or symptoms of acute infection requiring systemic therapy
  • No confusion, disorientation, or major psychiatric illness that would preclude giving informed consent
  • No serious infection requiring immediate therapy
  • No other illness requiring immediate therapy
  • No pre-existing retinopathy
  • No other medical or social factor that would preclude study compliance

PRIOR CONCURRENT THERAPY:

Biologic therapy

  • See Chemotherapy

Chemotherapy

  • No more than 2 prior chemotherapeutic regimens for recurrent or metastatic disease

    • Prior biologic therapy not considered a chemotherapeutic regimen

Endocrine therapy

  • More than 2 days since prior and no concurrent high-dose chronic steroids
  • More than 2 days since prior and no concurrent ethinylestradiol
  • No concurrent anticancer hormonal therapy

Radiotherapy

  • More than 6 months since prior radiotherapy
  • No concurrent radiotherapy

Surgery

  • No prior surgery that may affect the ability to swallow study drugs

Other

  • More than 2 days since prior and no concurrent cytochrome P450 3A4 (CYP3A4) inducers or inhibitors, including any of the following:

    • Gestodene
    • Itraconazole
    • Ketoconazole
    • Cimetidine
    • Erythromycin
    • Carbamazepine
    • Phenobarbital
    • Phenytoin
    • Rifampin
    • Sulfinpyrazone
    • Grapefruit juice
  • More than 30 days since prior high-dose vitamin A
  • No concurrent high-dose synthetic or natural vitamin A derivatives (> 10,000 IU/day)
  • No concurrent antioxidants (e.g., vitamin E or vitamin C)
  • No other concurrent investigational agents
  • No other concurrent antineoplastic agents
Both
Not Provided
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00103090
CDR0000411938, MDA-ID-01455, NCI-5709, SPRI-P03546, CDR0000411938, ID01-455
No
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
National Cancer Institute (NCI)
Study Chair: Edward S. Kim M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
November 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP